Reappraisal of β-blocker therapy in the acute and chronic post-myocardial infarction period

Reviews in Cardiovascular Medicine

Volumn 4, Issue SUPPL. 3, 2003, Pages

  Borrello, Francesco ^a   Beahan, Maribeth ^a   Klein, Liviu ^a   Gheorghiade, Mihai ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Blocker; Myocardial infarction

Indexed keywords

ACEBUTOLOL; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CARDIAC GLYCOSIDE; CARVEDILOL; CELIPROLOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METOPROLOL; NITRATE; PLACEBO; PROPRANOLOL; RAMIPRIL; TIMOLOL;

ACUTE HEART INFARCTION; AGE; ARTICLE; BRADYCARDIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; COLD TOLERANCE; DEPRESSION; DIABETES MELLITUS; DRUG CONTRAINDICATION; DRUG USE; FATIGUE; HEART FAILURE; HEART LEFT VENTRICLE CONTRACTION; HEART REINFARCTION; HUMAN; HYPOTENSION; LIBIDO DISORDER; LONG TERM CARE; MORTALITY; PERIPHERAL VASCULAR DISEASE; SEXUAL DYSFUNCTION; SIDE EFFECT;

ACUTE DISEASE; ADRENERGIC BETA-ANTAGONISTS; CHRONIC DISEASE; HUMANS; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; TIME FACTORS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0141505928     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. American Heart Association. Heart Disease and Stroke Statistics-2003 Update. Dallas, TX: American Heart Association; 2002. Available at http://www.americanheart.org.
2. Kober L, Torp-Pedersen C, Jorgensen S, et al. Changes in absolute and relative importance in the prognostic value of left ventricular systolic function and congestive heart failure after acute myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation. Am J Cardiol. 1998;81:1292-1297.
3. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined - a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol. 2000;36:959-969.
4. Smith SC Jr, Blair SN, Bonow RO, et al. AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation. 2001;104:1577-1579.
5. Tse WY, Kendall M. Is there a role for beta-blockers in hypertensive diabetic patients? Diabet Med. 1994;11:137-144.
6. Gheorghiade M, Bonow RO. Chronic heart failure in the United States: a manifestation of coronary artery disease. Circulation. 1998; 97:282-289.
7. Shah DJ, Diluzio S, Bello D, et al. Dobutamine echocardiography for predicting functional recovery of myocardium in heart failure patients treated with beta blocker therapy. Circulation. 2001;104(Suppl II):A518.
8. Hall SA, Cigarroa CG, Marcoux L, et al. Time course of improvement in left ventricular function, mass, and geometry in patients with congestive heart failure treated with β-adrenergic blockade. J Am Coll Cardiol. 1995; 25:1154-1161.
9. Bristow MR, Gilbert EM. Improvement in cardiac myocyte function by biological effects of medical therapy: a new concept in the treatment of heart failure. Eur Heart J. 1995;16(Suppl F):20-31.
10. Krumholz HM, Radford MJ, Wang Y, et al. National use and effectiveness of beta-blockers for the treatment of elderly patients after acute myocardial infarction: National Cooperative Cardiovascular Project. JAMA. 1998;280:623-629.
11. Gheorghiade M, Goldstein S. Beta-blockers in the post-myocardial infarction patient. Circulation. 2002;106:394-398.
12. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000;160:459-467.
13. Hjalmarson A, Elmfeldt D, Herlitz J, et al. Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomized trial. Lancet. 1981;2:823-827.
14. MIAMI Trial Research Group. Metoprolol in acute myocardial infarction (MIAMI). A randomized placebo-controlled international trial. The MIAMI Trial Research Group. Eur Heart J. 198S;6:199-226.
15. ISIS-1 Collaborative Group. Randomized trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group. Lancet. 1986;2:57-66.
16. Roberts R, Rogers WJ, Mueller HS, et al. Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction. Circulation. 1991;83:422-437.
17. Freemantle N, Cleland J, Young P, et al. Beta-blockade after myocardial infarction: systematic review and meta-regression analysis. BMJ. 1999;318:1730-1737.
18. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Long-term effects of intravenous thrombolysis in acute myocardial infarction: final report of the GISSI study. Lancet. 1987;2:871-874.
19. Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med. 1981;304:801-807.
20. Beta-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA. 1982;247:1707-1714.
21. CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomized trial. Lancet. 2001;357:1385-1390.
22. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321.
23. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med. 1998;339:489-497.
24. Krumholz HM, Radford MJ, Wang Y, et al. Early beta-blocker therapy for acute myocardial infarction in elderly patients. Ann Intern Med. 1999;131:648-654.
25. Chadda K, Goldstein S, Byington R, Curb JD. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation. 1986;73:503-510.
26. Gheorghiade M, Colucci WS, Swedberg K. β-Blockers in chronic heart failure. Circulation. 2003;107:1570-1575.
27. Chen J, Radford MJ, Wang Y, et al. Effectiveness of beta-blocker therapy after acute myocardial infarction in elderly patients with chronic obstructive pulmonary disease or asthma. J Am Coll Cardiol. 2001;37:1950-1956.
28. Tafreshi MJ, Weinacker AB. Beta-adrenergic-blocking agents in bronchospastic diseases: a therapeutic dilemma. Pharmacotherapy. 1999;19:974-978.
29. Chen J, Marciniak TA, Radford MJ, et al. Beta-blocker therapy for secondary prevention of myocardial infarction in elderly diabetic patients. Results from the National Cooperative Cardiovascular Project. J Am Coll Cardiol. 1999;34:1388-1394.
30. Kjekshus J, Gilpin E, Cali G, et al. Diabetic patients and beta-blockers after acute myocardial infarction. Eur Heart J. 1990;11:43-50.
31. Malmberg K, Ryden L, Hamsten A, et al. Mortality prediction in diabetic patients with myocardial infarction: experiences from the DIGAMI study. Cardiovasc Res. 1997;34:248-253.
32. Byington RP, Worthy J, Craven T, Furberg CD. Propranolol-induced lipid changes and their prognostic significance after a myocardial infarction: the Beta-Blocker Heart Attack Trial experience. Am J Cardiol. 1990;65:1287-1291.
33. Cruickshank JM. Beta-blockers, plasma lipids, and coronary heart disease. Circulation. 1990;82(Suppl 3):II60-II65.
34. Hedblad B, Wikstrand J, Janzon L, et al. Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). Circulation. 2001;103:1721-1726.
35. Giugliano D, Acampora R, Marfella R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med. 1997;126:955-959.
36. Hauf-Zachariou U, Widmann L, Zulsdorf B, et al. A double-blind comparison of the effects of carvedilol and captopril on serum lipid concentrations in patients with mild to moderate essential hypertension and dyslipidemia. Eur J Clin Pharmacol. 1993;45:95-100.
37. Jacob S, Rett K, Wicklmayr M, et al. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. J Hypertens. 1996;14:489-494.
38. Jacob S, Balletshofer B, Henriksen EJ, et al. Beta-blocking agents in patients with insulin resistance: effects of vasodilating beta-blockers. Blood Press. 1999;8:261-268.
39. Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001;344:1659-1667.
40. Yancy CW, Fowler MB, Colucci WS, et al. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med. 2001;344:1358-1365.
41. Heintzen MP, Strauer BE. Peripheral vascular effects of beta-blockers. Eur Heart J. 1994;15:2-7.
42. Nagakawa Y, Akedo Y, Kaku S, Orimo H. Effects of carvedilol on common carotid arterial flow, peripheral hemodynamics, and hemorheologic variables in hypertension. Eur J Clin Pharmacol. 1990;38(Suppl 2):S115-S119.
43. Bauriedel G, Skowasch D, Hofling B. [Carvedilol as vasodilating beta-blocker for the treatment of hypertensive patients with peripheral vascular disease-a pilot study]. Herz/Kreisl. 2000;32:69-73.
44. Gheorghiade M, Schultz L, Tilley B, et al. Effects of propranolol in non-Q wave acute myocardial infarction in the beta-blocker heart attack trial. Am J Cardiol. 1990;66:129-133.
45. Pedersen TR for the Norwegian Study Group. The Norwegian multicenter study of timolol after myocardial infarction. Circulation. 1983;67(Suppl 1):149-153.
46. Gibson RS, Beller GA, Gheorghiade M, et al. The prevalence and clinical significance of residual myocardial ischemia 2 weeks after uncomplicated non-Q wave infarction: a prospective natural history study. Circulation. 1986;73:1186-1198.
47. Beta-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. II. Morbidity results. JAMA. 1983;250:2814-2819.
48. American Medical Association. Beta-blocker prophylaxis after acute myocardial infarction. Quality care alert. Available at www.ama-assn.org. Accessed June 24, 2003.
49. Otterstad JE, Sleight P. The HOPE study: comparison with other trials of secondary prevention. Eur Heart J. 2001;22:1307-1310.
50. Otterstad JE, Ford I. The effect of carvedilol in patients with impaired left ventricular systolic function following an acute myocardial infarction. How do the treatment effects on total mortality and recurrent myocardial infarction in CAPRICORN compare with previous beta-blocker trials? Eur J Heart Fail. 2002;4:501-506.
51. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327:669-677.
52. Merit-HF Investigators Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001-2007.
53. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651-1658.